Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China
LBS-008 is Belite Bio’s orally administered tablet for early intervention to maintain the health of retinal tissue in Stargardt disease and Dry AMD patientsA 2-year Phase 2 trial in adolescent... | September 16, 2022